Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Nucl Med Commun. 2021 Oct 1;42(10):1076-1084. doi: 10.1097/MNM.0000000000001434.
Nucl Med Commun. 2021.
PMID: 34528928
Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.
Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S.
Kamaldeep, et al. Among authors: wanage g.
Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5.
Cancer Biother Radiopharm. 2021.
PMID: 32379495
Item in Clipboard
Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS, Parghane RV, Sahu S, Lad S, Deep K, Wanage G, Suralkar T, Banerjee S, Gupta S, Basu S, Badwe RA.
Narwadkar YS, et al. Among authors: wanage g.
Clin Nucl Med. 2024 Apr 1;49(4):e149-e155. doi: 10.1097/RLU.0000000000005067. Epub 2024 Feb 1.
Clin Nucl Med. 2024.
PMID: 38350067
Item in Clipboard
Cite
Cite